ArticleKidney diseases (Basel, Switzerland)
Telitacicept in IgA Nephropathy Patients with Severe Renal Impairment: A Case Series.
Article in Kidney diseases (Basel, Switzerland). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Treatment options for IgA nephropathy (IgAN) patients with severe renal impairment are limited. Although telitacicept is approved for reducing proteinuria in IgAN, prior trials excluded patients with estimated glomerular filtration rate (eGFR) <35 mL/min/1.73 m Methods: We retrospectively reviewed medical records of patients with biopsy-proven IgAN, eGFR 15-35 mL/min/1.73 m Results: Thirteen patients were included. Proteinuria decreased by 45% at month 6 and remained reduced by 51%, 47%, and 45% at months 12, 18, and 24, respectively. One patient initiated dialysis at month 15. Mean eGFR remained stable over 24 months, with an annual decline slope of -2.39 mL/min/1.73 m Conclusion: Telitacicept reduced proteinuria and stabilized eGFR in IgAN patients with severe renal impairment. It may be a therapeutic option for patients unresponsive or intolerant to conventional therapy, but confirmation in larger, prospective studies is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.